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The regulation of mitochondrial permeability, a key event in the initiation of apoptosis is governed
by the opposing actions of the pro- and anti-apoptotic members of the BCL2-family of proteins.
The BCL2-family can be classified further based on the number of BCL-homology (BH) domains
they encode. Pathogen mediated modulation of BCL2-family members play a significant role
in their ability to affect the apoptotic pathways in the infected host cell. The protozoan parasite
Toxoplasma gondii establishes a profound blockade of apoptosis noted by a requirement for
host NFκB activity and correlating with the selective degradation of pro-apoptotic BCL2-family
members. In this study, we explore the potential activities associated with the inherent stability
of the anti-apoptotic BCL2 as well as the selective degradation of the pro-apoptotic proteins
BAX, BAD, and BID. We find that multiple activities govern the relative stability of BCL2-family
members suggesting a complex and balanced network of stability-enhancing and–destabilizing
activities are perturbed by parasite infection. The data leave open the possibility for both parasite
induced host activities as well as the direct consequence of parasite effectors in governing the
relative levels of BCL2-proteins in the course of infection.
Keywords: Toxoplasma gondii, BCL2, apoptosis, NFκB, proteasome, protease inhibition

Introduction
The protozoan parasite Toxoplasma gondii is an important opportunistic infection in immune compromised individuals and a significant cause of birth defects when congenitally acquired (Tenter
et al., 2000). As an obligate intracellular pathogen, T. gondii has
successfully adapted to the intracellular environment (Boyle
and Radke, 2009). In doing so the parasite has evolved complex
mechanisms to interfere with or neutralize normal host defenses
(Boothroyd, 2009). Among these is the apoptotic cascade which we
and others have shown is profoundly inhibited in parasite infected
cells (reviewed in Carmen and Sinai, 2007). The inhibition of apoptosis is connected with the ability of T. gondii to manipulate the
NFκB pathway evidenced by the fact that the blockade of apoptosis
is lifted in NFκB (RelA/p65−/−) knock out cells (Payne et al., 2003).
While critically important, not all the anti-apoptotic events surrounding the blockade are channeled through NFκB as we recently
demonstrated with regard to the parasite mediated inhibition of
JNK activation in HeLa cells (Carmen et al., 2008).
The role of mitochondria in the activation of apoptosis is well
documented (Pinkoski et al., 2006; Wang and Youle, 2009). The key
triggering event committing a cell to apoptosis is the release of cytochrome c from the mitochondria inter-membrane space (Goldstein
et al., 2000; Gogvadze et al., 2006) resulting in the formation of the
apoptosome (Zou et al., 1999). The recruitment and activation of
the caspases in the apoptosome initiates the systematic dismantling
of the cell due to targeted degradation of critical caspase substrates
(Abu-Qare and Abou-Donia, 2001; Baliga and Kumar, 2003). The
release of cytochrome c is therefore under tight regulatory control.
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Much of this control is mediated by the opposing actions of the
anti-apoptotic and pro-apoptotic members of the BCL2-family of
proteins (Scorrano and Korsmeyer, 2003; Brunelle and Letai, 2009).
These proteins are classified based on their activity and the number
of BCL2-homology (BH) domains (reviewed in Thomadaki and
Scorilas, 2008; Brunelle and Letai, 2009). Accordingly the antiapoptotic BCL2 contains four BH domains (BH1, 2, 3, 4; Liston
et al., 2003). Among the pro-apoptotic members are the multidomain protein (BAX, containing BH1, 2, 3; Lalier et al., 2007)
and the BH3 only proteins BAD and BID (Marsden and Strasser,
2003). The anti-apoptotic BCL2 actively interferes with permeabilization of the mitochondrial outer membrane (MOM) by the multidomain proteins (e.g., BAX) thus blocking apoptosis (Thomadaki
and Scorilas, 2008; Brunelle and Letai, 2009). Displacement of the
protective BCL2 from BAX is mediated by members of the BH3 only
sub-family thus promoting apoptosis (Thomadaki and Scorilas,
2008; Brunelle and Letai, 2009). Although controversial, BH3 only
proteins may exert their effect additionally by the direct activation
of BAX (Wu and Deng, 2002). Regardless of the mechanism of
action, BH3 only proteins shift the balance toward a pro-apoptotic
state. This stringent and nuanced level of control over the release
of cytochrome c is susceptible to pathogen manipulation.
Manipulation of the BCL2-family has been observed for viral
(Galluzzi et al., 2008), bacterial (Faherty and Maurelli, 2008), and
protozoan pathogens (Carmen and Sinai, 2007). The consequence
of this manipulation is to either promote or inhibit apoptosis,
resulting in an outcome that is advantageous to the specific pathogen. Our earlier work demonstrated that infection of mammalian
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cells by T. gondii results in the selective degradation of pro-apoptotic
BCL2-family members (BAD, BAX) while the anti-apoptotic BCL2protein remained relatively unaffected (Carmen et al., 2006). With
this study we investigate the contribution of NFκB, a key player
in the parasite enforced blockade of apoptosis (Payne et al., 2003;
Carmen and Sinai, 2007), as well as the roles of specific classes of
proteolytic activities (Otlewski et al., 2005) on the selective parasite
induced degradation. The results indicate that multiple activities
target the specific proteins to ensure their stability. The data further
suggest the differential stability profiles in response to infection
may be due to both the direct impact of parasite activities as well
the induction of host cell activities. In addition to increasing our
understanding of the molecular basis for the T. gondii enforced
block of apoptosis, additional insights into the biology of the BCL2family of proteins are revealed.

Materials and Methods
Cell and parasite maintenance

Wild type mouse embryonic fibroblasts [WT MEF (line WT-1)]
and the NFκB p65−/− mouse embryonic fibroblast line RelA-2
(Gapuzan et al., 2005), graciously provided by Dr. Alexander
Hoffmann (University of California, San Diego), were maintained in α-minimal essential medium (α-MEM) supplemented
with 100 units ml−1 penicillin, 100 μg ml−1 streptomycin, 7% heatinactivated fetal bovine serum and 2 mM l-glutamine (Gibco
Invitrogen, Carlsbad, CA, USA). The RH strain of T. gondii with a
deletion in the hypoxanthine-xanthine-guanine-phosphoribosyltransferase (HXGPRT) gene (Donald and Roos, 1998) was used in
these experiments (NIH AIDS Research and Reference Program).
Parasites were maintained by serial passage in Vero cells as described
previously (Payne et al., 2003).
Analysis of the effect of T. gondii infection on BCL2, BAX, BAD,
and BID levels

The effect of infection on the levels of BCL2, BAX, BAD, and BID
was determined in WT MEF or p65−/− (RelA-2) MEF (Gapuzan
et al., 2005) infected with increasing numbers of parasites [multiplicity of infection (MOI) = 0, 2, 4, 6, 8, or 10 tachyzoites per
cell]. Cells were seeded into six-well dishes and incubated at 37°C
for 8 h. Prior to infection, T. gondii tachyzoites were harvested,
washed with PBS, and counted. The parasites were diluted in complete α-MEM, added to the six-well dishes, and the dishes were
returned to a 37°C incubator for 20 h. After this incubation, the
cells were harvested, resuspended in 1.0% Triton x-100 in PBS and
centrifuged at 10,000 rpm for 7 min to remove insoluble material.
The total protein concentration of the resulting supernatant was
determined using a BCA Protein Assay Kit (Pierce Biotechnology,
Inc., Rockford, IL, USA) and equal amounts of total protein were
resolved via SDS-PAGE on 12% gels and analyzed via immunoblot as described previously (Payne et al., 2003). Blocking of
immunoblots was performed with 5% bovine serum albumin in
phosphate buffered saline containing 0.2% Tween 20. The antibodies used were: mouse monoclonal anti-BCL2 (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA, USA, sc-7382), mouse monoclonal anti-BAX (1:500, Santa Cruz Biotechnology, Santa Cruz,
CA, USA, sc-7480), rabbit polyclonal anti-BAD (1:12,000, Stressgen
Bioreagents, Ann Arbor, MI, USA, AAP-020), and rabbit polyclonal
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anti-BID (1:4000, Santa Cruz Biotechnology, Santa Cruz, CA, USA,
sc-11423). Blots were stripped and reprobed with an anti-calnexin
antibody to verify equal protein loading as previously described
(Carmen et al., 2008). Detection of reactive proteins was achieved
using enhanced chemiluminescence (Pierce) recorded on X-ray
film (Fuji) as previously described (Carmen et al., 2006).
Inhibition of the proteasome and specific protease classes

Proteasome/protease inhibitor studies were performed using the
following experimental design. Cells were seeded into six-well
dishes and, after an 8-h incubation period, infected at the MOI
described in the figure. Uninfected and infected cells were incubated
with the various inhibitors for the last 8 h of a 24-h infection period.
At the end of inhibitor treatment, cells were harvested and analyzed
using SDS-PAGE and immunoblotting. The role of the proteasome in T. gondii-dependent BCL2-family member degradation
was determined by analyzing the levels of BCL2, BAX, BAD, and
BID in cells treated with 20 μM MG132. The MG132 stock solution
was made in DMSO and an equal volume of the carrier was added to
the untreated samples. The protease inhibitors E64d, leupeptin, and
Nα-tosyl-phenylalanyl chloromethyl ketone (TPCK) were used to
experimentally determine the role of cysteine proteases (E64d) and
the trypsin-like serine proteases (leupeptin) and chymotrypsin-like
serine proteases (TPCK) in the T. gondii-dependent degradation
of BCL2-family members. Leupeptin (Sigma Aldrich, Milwaukee,
WI, USA, L2023) was dissolved in sterile distilled water and used
at a final concentration of 10 μg ml−1 leupeptin in α-MEM. TPCK
(Sigma, Milwaukee, WI, USA, T4376) in DMSO was diluted in
α-MEM to a final working concentration of 10 μM. The E64d
stock (Sigma Aldrich, Milwaukee, WI, USA, E8640) was dissolved
in 50% methanol and diluted into the medium to a concentration
of 100 μM. In experiments using inhibitors dissolved with solvents
other than water, control cells were treated with α-MEM containing
an identical volume of the solvent as the inhibitor α-MEM.
Densitometric analysis of the immunoblots and data
analysis

Normalized protein levels were determined using densitometric
analysis. This was performed using ImageJ software (National
Institutes of Health, Bethesda, MD, USA) to calculate the integrated
density of both the band of interest (BCL2, BAX, BAD, or BID)
and the corresponding loading control band (calnexin). Multiple
immunoblot exposures were scanned into digital files and opened
using ImageJ software. The background was subtracted from the
image using the subtract background function and the image was
inverted. The membranes had been exposed to film for multiple
lengths of time and the exposure judged to be in the linear range
was quantitated. Normalized protein level values represent the
integrated density value (IDV) of the band of interest divided by
the integrated density of the loading control band (e.g., BCL2/calnexin). Finally, the resulting values for multiple experiments were
averaged and the SD was calculated. Given the variability of the
data the following considerations went into the exclusion of specific
experiments. (1) The presence in any lane of a given experiment
of a protein of interest/calnexin ratio >2.5 was typically due to a
problem with the loading control (data not shown) and was therefore excluded. (2) Immunoblots with a high uneven background
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level impinging on bands of interest were also excluded. Using the
criteria for exclusion a minimum of four independent experiments
were recorded for a given condition. The specific number of experiments employed in the statistical analysis is indicated in the figure
legend for each sample.
Statistical Analyses

The IDV values comprising the ratio of exposure level of the protein
of interest relative to calnexin were analyzed using the GraphPad
Prism software program. The data are presented in a graphical form
as the mean for the specific sample with the error bars corresponding to the SE of the mean. In addition, we performed One-way
analysis of variance (ANOVA) tests using the Repeated Measures
Test. The repeated measures test is ideal given the experimental
design as matched subjects are used in each experimental replicate.
Accordingly, the variance in the relative level of the specific protein
is measured across the MOI range for the specific experimental
parameter. Thus the significance of the trend across the MOI range
can be established. The level of significance was set at a p-value
of <0.05.
The repeated test ANOVA analyses for the effect of the inhibitors used (Figures 3–6) are noted in Table 1. In addition to the
analysis of the specific trends, the Dunnett test, whereby pairwise
comparisons of significance (set at p < 0.05) are made for a given
MOI relative to the uninfected control, was used. The MOI’s meeting this criterion are marked with an asterisk in the figures.
Finally, we established a representational scale based on the
relative sensitivity of the protein to infection-mediated degradation. This scale follows the trend of the mean relative protein level
pointing to specific trend whether or not it is statistically significant at the established p < 0.05 for the given data set. Accordingly
proteins exhibiting degradation at a MOI = 2 or 4 (+++) are
highly sensitive, proteins for which the onset of degradation is at
MOI – 6 to 8 are moderately sensitive (++) while those showing
degradation at MOI = 10 are deemed marginally sensitive (+).
Those proteins that fail to show any degradation based on the
quantified results are insensitive to infection-mediated degradation (−; Table 1).

Results
Differential sensitivity of BCL2-family members to infectionmediated degradation

We previously reported that T. gondii infection induces the selective loss of pro-apoptotic BCL2-family proteins in an infectious
dose dependent manner (Carmen et al., 2006). In addition, studies on host transcriptional changes in response to infection fail to
explain the specific loss of pro-apoptotic BCL2-family proteins
(Molestina et al., 2003). In order to rigorously address the phenotype we reexamined the apparent selective degradation of proapoptotic BCL2-proteins using the more quantitative approaches
described in the material and method. In our analyses we examined
the anti-apoptotic protein BCL2, the multi-domain pro-apoptotic
member BAX, and two BH3-only pro-apoptotic proteins BAD and
BID (Thomadaki and Scorilas, 2008). Analysis of this nature is
subject to considerable variation from experiment to experiment.
Applying a ratiometric approach addresses some of this variability.
Specific criteria for the inclusion of data are summarized in the
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Section “Materials and Methods.” Notably, in addition to defining
the mean and SE we performed repeated measures ANOVA comparing the levels of significance for the infection level dependent
loss of specific BCL2-family proteins. In addition, significant differences were recorded in pairwise comparisons relative to uninfected
controls.
Consistent with previously published work we report that
increasing T. gondii infection levels (MOI from 2 to 10) results in
differential impacts on the anti-apoptotic BCL2-protein and the
pro-apoptotic proteins BAX, BAD, and BID (Carmen et al., 2006).
The BCL2-protein remains largely stable in the face of infection
(Figure 1A). In compiling data from multiple independent experiments this trends is validated with a small though statistically insignificant dip at the highest MOI (Figure 1B). Overall the degradation
of BCL2 across the entire infection range (MOI) was found not
be significant (p-value 0.0899). In contrast the multi-domain proapoptotic BAX is highly susceptible to infection-mediated degradation as evidenced in the representative gel (Figure 1A) and from
the compiled quantitative data which shows a significant reduction
in BAX steady state levels with an MOI of 2 and 4 (Figures 1A,B;
p-value < 0.0001). The BH3-only proteins BAD and BID exhibit
an intermediate phenotype being moderately sensitive (at MOI of
6–8) to infection-mediated degradation (Figures 1A,B; p-values
of 0.0265 and 0.0083 respectively).
Host NFκB activity alone is not the basis of the differential
stability in response to infection

Our previous studies have established NFκB as an important mediator of the parasite-blockade of apoptosis (Molestina et al., 2003;
Payne et al., 2003). This relationship however is not universally
applicable to all aspects of apoptosis as NFκB shows no involvement in the infection-mediated block of JNK activation a key event
in UV induced apoptosis (Carmen et al., 2008). The availability of
RelA/p65−/− fibroblasts (Gapuzan et al., 2005) allows us to directly
investigate the role of the intact NFκB cascade on the parasite mediated degradation of BCL2-family proteins.
In the absence of NFκB activity we observe what appears to be
increased sensitivity of BCL2 to infection-mediated degradation
with some protein loss at an MOI of 6 (Figures 2A,B). However
this difference was not seen to be statistically significant (Figure 2C,
p-value 0.7071). Likewise, the apparent trend for the multi-domain
member BAX was sustained relative to infection of WT MEF’s
(Figures 2A–C). This trend was not found to be statistically significant (p-value 0.1122). In contrast the BH3-only members BAD
and BID exhibited some stabilization with appreciable degradation
only at the highest MOI (Figures 2A–C). Overall the data indicate
that the post transcriptional stability of BCL2-family members is
not significantly regulated by NFκB dependent activities.
Inhibition of proteasomal degradation selectively impacts
the BH3-only family members

Proteasome mediated protein degradation is involved in the regulated turnover of diverse cellular proteins (Hoff et al., 2004). Proteins
are targeted for degradation by their ubiquitination (Hoff et al.,
2004). The drug MG132 is readily membrane permanent and irreversibly blocks the activity of the proteasome (Lee and Goldberg,
1998). We reasoned that treatment of infected cells using MG132
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Figure 1 | The effect of Toxoplasma gondii infection on the steady state
levels of the BCL2-family proteins in WT MEF. (A) Representative
immunoblots detecting the levels of the anti-apoptotic BCL2, pro-apoptotic
multi-domain member BAX and the BH3-only proteins BAD and BID in
response to increasing infection (multiplicity of infection range 0 (uninfected)
to 10). The signal for calnexin is used as a loading control. (B) Quantification of
the relative levels of BCL2-family proteins relative to the corresponding signal
for calnexin in response to infection at a given MOI. The multiplicity of infection
for a given protein is denoted in the parenthesis following the name of the
target protein. Using criteria outlined in the Section “Materials and Methods,”

the following number of independent experiments were used to assemble the
presented data: BCL 2–8 experiments, BAX-10 experiments, BAD-8
experiments and BID-6 experiments. The error bars represent the SE of the
mean (symbol). A single asterisk above an error bar signifies a significant data
point relative to the uninfected control with a p-value <0.05 employing the
Dunnett pairwise test. (C) Repeated measures ANOVA analysis relative to the
uninfected control was performed. A p-value of 0.05 or higher were
considered to be not significant (ns). Values of low significance (*0.01–0.05),
moderate significance (**0.001–0.01), highly significant (***<0.001)
were used.

Figure 2 | The effect of Toxoplasma gondii infection on the steady state
levels of the BCL2-family proteins in NFκB knock out fibroblasts
(p65−/− MEF). (A) Representative immunoblots detecting the levels of the
anti-apoptotic BCL2, pro-apoptotic multi-domain member BAX and the BH3-only
proteins BAD and BID in response to increasing infection [multiplicity of
infection range 0 (uninfected) to 10]. The signal for calnexin is used as a loading
control. (B) Quantification of the relative levels of BCL2-family proteins relative
to the corresponding signal for calnexin in response to infection at a given MOI.
The multiplicity of infection for a given protein is denoted in the parenthesis

following the name of the target protein. Using criteria outlined in the Section
“Materials and Methods,” the following number of independent experiments
were used to assemble the presented data: BCL2–5 experiments, BAX-4
experiments, BAD-4 experiments and BID-4 experiments. The error bars
represent the SE of the mean (symbol). Specific data points with asterisk define
a statistically significant difference (p < 0.05) in a pairwise test relative to the
uninfected control. (C) Values for a repeated measures ANOVA across the MOI
range for each protein indicates no significant overall change in NFκB deficient
cells in response to infection.
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as described in Figure 3A would establish a role for proteasome
mediated turnover of the BCL2-family proteins in response to infection. Our reasoning was that in the presence of the inhibitor steady
state levels of the proteins would increase if proteasome-mediated
turnover was responsible for the degradation of the specific protein. On account of the inherent variability in such experiments we
conducted repeated measure ANOVA across the MOI range for the
treated samples and their matched controls (Table 1).
The levels of none of the BCL2-family proteins were
enhanced (higher relative levels at MOI = 0) in non–infected
cells (Figures 3B,C). However, the steady state level for BID was

Figure 3 | Effect of proteasome inhibition with MG132 on the steady state
levels of BCL2-family proteins in both uninfected (MOI = 0) and infected
(MOI 2–10) cells. (A) Experimental strategy for the establishment of infection
and treatment with the inhibitor. (B) Representative immunoblots detecting the
levels of the indicated BCL2-family members in response to increasing infection.
Levels of calnexin are used as a loading control. (C) Quantification of the levels of
specific BCL2-proteins relative to calnexin in response to increasing infecting
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 arkedly reduced in drug treated uninfected cells (MOI = 0). This
m
would suggest that a proteasome-sensitive stabilizing activity is
involved in the normal turnover of BID (Figures 3B,C). Such a factor could be akin to a protease inhibitor, whose expression, turnover
or activity could be impacted.
Interestingly, while MG132 failed to have any effect on the
stability of BCL2 and BAX in response to infection, the capacity
to degrade BAD and BID by the infection-mediated component
was effectively lost (Figure 3C). This is noted in the essentially
flat profile of the curve for MG132 treated BAD and BID cells
(Figure 3C). MG132 is known to be an inhibitor of NFκB due to

dose. Profiles for no-treatment (NT, DMSO) and treated (MG132) samples are
indicated along with the MOI in parentheses. The mean relative level is indicated
by the symbol with the error bards representing the SE of the mean. A single
asterisk above an error bar signifies a significant data point relative to the
uninfected control with a p-value <0.05 employing the Dunnett pairwise test. The
data presented were derived four independent replicates for each BCL2-family
member. ANOVA data from this experiment are compiled in Table 1.
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Table 1 | Impact of proteasome and protease inhibition on the stability of BCL2-family proteins in uninfected cells and in response to infection.
Inhibitors

BCL2

BAX

BAD

BID

Proteasome
MG132 alone

No effect

No effect

No effect

Decreased stability

Infection + MG132

NT (+/−)

MG132 (+/−)

NT (+++)

MG132 (+++)

NT (++)

MG132 (+/−)

NT (+++)

MG132 (+/−)

ANOVA

0.8123

0.9926

0.0037

0.1067

0.0894

0.8026

0.0020

0.9314

Cysteine proteases
E64d alone

No effect

Increased stability

No effect

Decreased stability

Infection + E64d

NT (+/−)

E64d (+/−)

NT (+/−)

E64d (+++)

NT (+++)

E64d (++)

NT (+++)

E64d (+++)

ANOVA

0.8395

0.5688

0.1914

0.0001

0.0074

0.0100

0.0244

0.0231

Trypsin-like
Leupeptin alone

No effect

Increased stability

No effect

Increased stability

Infection + Leu

NT (+/−)

LEU (−)

NT (+++)

LEU (+++)

NT (++)

LEU (+/−)

NT (+++)

LEU (+/−)

ANOVA

0.6567

0.3139

0.0016

0.0008

0.0283

0.6257

0.0110

0.3831

Chymotrypsin-like
TPCK alone

No effect

Increased stability

Decreased stability

Decreased stability

Infection + TPCK

NT (+/−)

TPCK (+/−)

NT (+++)

TPCK (+++)

NT (++)

TPCK (+/−)

NT (+++)

TPCK (+/−)

ANOVA

0.6773

0.3189

0.0122

0.0065

0.0157

0.3410

0.0059

0.3147

The sensitivity to degradation is classified using a scale correlating the multiplicity of infection (MOI) required for substantial loss of steady sate levels of the given
protein. Accordingly, highly sensitivity to infection induced degradation (MOI of 2 or 4): +++, moderately sensitive to infection induced degradation (MOI of 6–8):
++, marginally sensitive to infection induced degradation (MOI of 10: +, insensitive to infection induced degradation: −). Additionally values from repeated measures
ANOVA are presented. p-Values <0.05 are considered significant. NT, no-treatment.

the block in the degradation of the ubiquitinated Phospho-IκBα,
the inhibitor of NFκB (Karin and Lin, 2002; Giuliano et al., 2003).
It is therefore interesting that the pattern for infection-mediated
degradation of BAD and BID follows a profile similar to that in
infected RelA/p65−/− cells with the onset of degradation occurring at the highest MOI (Figure 2). This suggests that an NFκBregulated proteolytic activity is involved in the parasite-directed
degradation of BH3-only proteins. Conversely enhanced stability of a protease inhibitor following proteasome inhibition could
explain the absence of the infection-dependent degradation of
these BH3 only proteins. The effects of MG132 on the parasite
mediated degradation of BCL2-family proteins was subjected to
ANOVA analysis. As reported in Table 1, MG132, resulted in the
loss of infection-mediated degradation of BAD and BID with a
similarly pronounced effect on BAX. BCL2 itself was unaffected
when comparing the profiles for untreated and MG132 treated
samples across the MOI range.
Cysteine proteases differentially impact the pro-apoptotic
BCL2-family members

The membrane permeable cysteine protease inhibitor E64d
(Hernandez and Roush, 2002; Lindvall, 2002) was used to establish
the role of this class of proteolytic activities in stability of BCL2family member. Inhibitor treatment using a regimen identical to
that above (Figure 3A) indicates that the inhibition of cysteine
proteases has no significant effect on BCL2 levels and causes a
small increase in the stability of BAX in the absence of infection
(MOI = 0; Figures 4A,B). There was no effect on the inherent
stability of BAD; however, E64d treatment resulted in a marked
reduction in steady state BID levels. The effect on BID mirrors that
seen for MG132 (Figure 3). Interestingly, the infection-mediated
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degradation of all of the BCL2-family proteins, except for BAX,
was largely unaffected by E64d treatment as the general patterns
for infection-mediated BCL2 member degradation was similar in
treated and untreated samples (Figure 4). For all but BAX, the
ANOVA values are similar when comparing untreated (NT) to the
E64d treated samples. In the case of BAX however E64d resulted
in a highly significant loss of variability at all the MOI’s examined
(Figure 4B; Table 1).
Inhibition of “trypsin-like” serine proteases has differential
effects on BCL2-family members

Leupeptin is a broad spectrum membrane permeant inhibitor
of trypsin-like serine protease activities (Kurinov and Harrison,
1996). Treatment of uninfected cells (MOI = 0) with leupeptin
using the strategy presented in Figure 3A resulted in no effect for
BCL2, BAX, or BAD (Figure 5). In contrast the mean steady state
level of the BH3-only protein BID was enhanced in the presence
of leupeptin (Figure 5), although the error bars are pronounced.
These data would suggest that normal turnover of BID is mediated by a trypsin-like activity which, when inhibited, results in the
accumulation of the protein in uninfected cells.
We examined the effect of leupeptin on the infection-mediated
degradation of the BCL2-family proteins. While not affecting the
levels in BCL2 in uninfected cells, levels of the protein trended in
an upward direction with increasing infection (Figure 5). This
upward trend, however, was not statistically significant based on
ANOVA analysis (Table 1). There was no effect on the infectiondependent degradation of BAX (Figure 5; Table 1). In contrast,
in the presence of leupeptin the infection-mediated degradation
of BAD was reduced, with the protein becoming marginally sensitive to degradation (Figure 5; Table 1). Interestingly the marked

January 2011 | Volume 2 | Article 1 | 6

Carmen and Sinai

T. gondii manipulation of BCL2-family proteins

Figure 4 | Effect of cysteine protease inhibition with E64d on the steady
state levels of BCL2-family proteins in both uninfected (MOI = 0) and
infected cells (MOI 2–10). (A) Representative immunoblots detecting the levels
of the indicated BCL2-family members in response to increasing infection.
Levels of calnexin are used as a loading control. (B) Quantification of the levels
of specific BCL2-proteins relative to calnexin in response to increasing infecting
dose. Profiles for no-treatment (NT, untreated) and treated (E64) samples are

indicated along with the MOI in parentheses. The mean relative level is indicated
by the symbol with the error bards representing the SE of the mean. A single
asterisk above an error bar signifies a significant data point relative to the
uninfected control with a p-value <0.05 employing the Dunnett pairwise test.
The data presented were derived from three independent replicates for each
BCL2-family member. ANOVA data from this experiment are compiled
in Table 1.

reduction in variability of BAD levels was seen only for this protein in the presence of leupeptin. This phenotype is exactly the
opposite to what was observed for BID, where steady state levels
were seen to become, highly variable on account of leupeptin.
Furthermore, the effect of leupeptin in increasing the steady
state levels of BID in uninfected cells, did have an impact on the
infection-mediated turnover as that effect was blunted (ANOVA
p-value 0.011 in untreated and 0.3831 in treated samples; Figure 5;
Table 1). This indicates a distinct activity from that involved in
the normal leupeptin-sensitive turnover of BID is present in the
parasite infected cell. This could be either a host activity induced
in the infected cell or a parasite derived activity secreted into the
host cytoplasm.

“Chymotrypsin-like” serine proteases differentially impact
pro-apoptotic BCL2-family members

www.frontiersin.org

The chymotrypsin-like proteases can be inhibited by TPCK
(Frydrych and Mlejnek, 2008). TPCK treatment of infected cells
using the modality in Figure 3A indicates that BCL2 levels are
not controlled by a chymotrypsin –like serine protease (Figure 6;
Table 1). In contrast, treatment of uninfected cells (MOI = 0) with
TPCK resulted in the accumulation of the multi-domain family
member BAX (Figure 6; Table 1) but reduced levels of both the
BH3-only proteins BAD and BAX (Figure 6). Furthermore, levels
of BAD were fount to be quite variable. This differential effect on
the pro-apoptotic BCL2-family suggests that chymotrypsin-like
activities may degrade BAX directly. The reduced steady state levels
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Figure 5 | Effect of trypsin-like serine protease inhibition with leupeptin
on the steady state levels of BCL2-family proteins in both uninfected
(MOI = 0) and infected cells (MOI 2–10). (A) Representative immunoblots
detecting the levels of the indicated BCL2-family members in response to
increasing infection. Levels of calnexin are used as a loading control.
(B) Quantification of the levels of specific BCL2-proteins relative to calnexin
in response to increasing infecting dose. Profiles for no-treatment (NT,
untreated) and treated (Leu) samples are indicated along with the MOI in

of both BH3 only proteins suggest an indirect effect where the
inhibition of TPCK may result in the stabilization of a degradative
activity with a distinct inhibitor profile.
Chymotrypsin-like serine protease activities do not appear to
play a role in the infection-mediated turnover of BCL2 or BAX.
However the activities associated with the infection-mediated
degradation of the BH3-only proteins BAD and BID are inhibited as evident from the slope of the curves in response to the
increasing infection dose. This trend is validated by the ANOVA
data indicating a marked loss of variability in levels of these proteins due to infection (Table 1). Thus we can conclude that the
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parentheses. The mean relative level is indicated by the symbol with the error
bards representing the SE of the mean. A single asterisk above an error bar
signifies a significant data point relative to the uninfected control with a
p-value <0.05 employing the Dunnett pairwise test. The data presented were
derived from four independent replicates for each BCL2, BAX, BID, and
untreated BAD samples. Three independent experiments were used for the
BAD immunoblots with leupeptin treatment. ANOVA data from this
experiment are compiled in Table 1.

i nfection-mediated degradation of the BH3-only proteins involves
serine protease activities (both trypsin- and chymotrypsin-like)
that may be induced in response to the infection or be secreted
directly by the parasite.

Discussion
The key triggering event in the induction of apoptosis along the
intrinsic pathway is the release of cytochrome c from mitochondria
resulting in the activation of the initiator and eventually executioner
caspases (Pinkoski et al., 2006; Wang and Youle, 2009). The caspases
systematically and irreversibly dismantle key activities ensuring the
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Figure 6 | Effect of chymotrypsin-like serine protease inhibition with
TPCK on the steady state levels of BCL2-family proteins in both
uninfected (MOI = 0) and infected cells (MOI 2–10). (A) Representative
immunoblots detecting the levels of the indicated BCL2-family members in
response to increasing infection. Levels of calnexin are used as a loading
control. (B) Quantification of the levels of specific BCL2-proteins relative to
calnexin in response to increasing infecting dose. Profiles for no-treatment (NT,
untreated) and treated (TPCK) samples are indicated along with the MOI in

progression to an apoptotic death. Given the finality of cell death,
cytochrome c release is under tight regulation (Goldstein et al.,
2000; Gogvadze et al., 2006). The pro- and anti-apoptotic arms of
the BCL2-family proteins govern the balance of activities ensuring maintenance of cell viability or committing it to an apoptotic
death (Scorrano and Korsmeyer, 2003; Brunelle and Letai, 2009).
The BCL2-family is defined by the presence of the BH domains.
The anti-apoptotic protein BCL2 possesses BH1, 2, 3, and 4 (Liston
et al., 2003). Among the pro-apoptotic proteins BAX is a multidomain (BH1, 2, 3) protein (Lalier et al., 2007) while both BAD and
BID possess only the BH3 domain (Marsden and Strasser, 2003).
In multicellular organisms, apoptosis provides an effective defense
mechanisms against pathogen attack by sacrificing an infected
cell thus controlling the pathogens capacity to replicate(Hasnain
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parentheses. The mean relative level is indicated by the symbol with the error
bards representing the SE of the mean. A single asterisk above an error bar
signifies a significant data point relative to the uninfected control with a
p-value <0.05 employing the Dunnett pairwise test. The data presented were
derived from five independent replicates for BCL2, BAD, and BID. Five
independent replicates were used for untreated BAX samples while four were
included for the TPCK treated condition. ANOVA data from this experiment are
compiled in Table 1.

et al., 2003). As a countermeasure, pathogens have evolved elaborate
mechanism to disrupt the apoptotic response (Barry and Beaman,
2006; Carmen and Sinai, 2007; Faherty and Maurelli, 2008; Galluzzi
et al., 2008).
As an obligate intracellular parasite, T. gondii is critically dependent on its ability to block apoptosis (Carmen and Sinai, 2007). This
blockade is established at multiple levels involving the transmission
of an apoptotic signal, the triggering of the apoptogenic response
and finally its execution. Our studies have firmly established a
vital role for the transcription factor NFκB in the establishment
of the overall apoptotic stage (Molestina et al., 2003; Payne et al.,
2003; Molestina and Sinai, 2005a,b). However the role of NFκBmediated effects is not universal when examining how the parasite
impacts specific components in the apoptotic process. Accordingly,
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while the inhibition of caspase activity is completely dependent on
NFκB-regulated components, the infection-mediated inhibition of
JNK-kinases following UV irradiation is independent of it (Carmen
et al., 2006, 2008) despite evidence for considerable crosstalk
between the NFκB and JNK pathways (Papa et al., 2006; Wullaert
et al., 2006). The complexity of the response is further evident
in the differential response of BCL2-family proteins to infection
as seen in multiple studies. As a whole, multiple studies demonstrate that T. gondii infection shifts the balance of BCL2-proteins
to favor an anti-apoptotic state (Goebel et al., 2001; Carmen et al.,
2006; Hippe et al., 2009a,b). This shift is evident from the selective degradation of pro-apoptotic BCL2-family proteins and the
relative resistance to degradation of the anti-apoptotic members
(Carmen et al., 2006). A pathogen mediated selective degradation
of pro-apoptotic BCL2-family proteins has also been reported in
Chlamydia infected cells (Zhong et al., 2001; Dong et al., 2005; Ying
et al., 2005). The phenotype of infection-dependent degradation
may be connected to the parasite strain as others, using an avirulent
Type II isolate fail to observe this phenotype (Hippe et al., 2009b).
In their study, they point out that in the absence of quantification
in our prior work the degradation phenotype was not delineated
(Hippe et al., 2009a). We chose to delve deeper into the potential
mechanistic basis of this response by investigating the involvement
of NFκB-mediated regulation as well as the selective inhibition
of specific classes of proteases. We further examine the response
quantitatively and confirm that the selective degradation of proapoptotic BCL2-family members does in fact occur in response to
Toxoplasma infection and present potential mechanisms for what
is a complex phenotype.
The steady state level of any protein is governed by the balance
of its inherent stability and its rate of synthesis. In pilot studies we
blocked de novo protein synthesis using cycloheximide and monitored the levels of BCL2-family proteins over time. These studies
indicate a half life for BCL2 of around 6 h while that of BAD and
BID was >8 h (data not shown). Interestingly, the multi-domain
protein BAX exhibited a half life of around 2 h suggesting a relatively high turnover (data not shown). This relative instability is
reflected in the fact that BAX was found to be the most susceptible
to infection-mediated degradation (Figure 1). Notably, the rates
of degradation in response to infection for the BH3 only proteins
BAD and BID exhibited moderate sensitivity (MOI 6–8; Figure 1).
The anti-apoptotic BCL2-protein, which possesses BH1, 2, 3 and
BH4 domains was inherently resistant to degradation (Figure 1)
suggestive of a protective effect derived from the BH4 domain and/
or the increased expression as suggested from the transcriptional
data (Molestina et al., 2003 and data not shown). Together the
spectrum of responses is consistent with a complex network of
activities at play.
The role of NFκB in the regulation of the apoptotic cascade is
well documented (Karin and Lin, 2002). Transcriptional data on
infected cells indicates that the anti-apoptotic proteins BCL2 and
BFL1 are upregulated with BFL1 induction being strongly dependent on NFκB (Molestina et al., 2003). In contrast infection fails to
have any transcriptional consequence on the pro-apoptotic proteins (Molestina et al., 2003 and data not shown). Interestingly,
while BAX degradation was unchanged in RelA/p65−/− MEF’s the
stability of BCL2 was compromised while that of the BH3 only
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proteins BAD and BID enhanced (Figure 2). Taken together the
data suggest that NFκB differentially impact the different classes
of BCL2-family of proteins during infection and that the trends
correlate with a role for NFκB in establishing the anti-apoptotic
state along the BCL2-family axis. It further suggests that multiple
activities, potentially defined by the class of specific protein being
targeted, governs its stability in the course of infection.
Protein turnover is governed by the activities of distinct degradative mechanisms including the proteasome and a spectrum of
proteases. We used well established membrane permeant inhibitors of the proteasome (MG132), cysteine proteases (E64d), and
serine proteases: including trypsin-like proteases (leupeptin) and
chymotrypsin-like proteases (TPCK), to evaluate the impact on
the stability of the BCL2-family proteins in response to infection.
The lack of availability of membrane permeant inhibitors of other
protease classes precluded analysis of their impact in intact cells.
The results which are summarized in Table 1 confirm the complexity of the networks governing turnover of these proteins in
infected cells. The data in Table 1 represents a summary of the
information presented in the figures dealing with the inhibition
studies (Figures 3–6).
Our basic rationale was that the inhibition of a proteolytic activity would result in the accumulation of a target protein. In contrast,
a reduction in the steady state level of a target protein following
treatment with an inhibitor would suggest that the specific target may be an inhibitory, and therefore stabilizing activity. Thus
loss of a protease inhibitor would increase steady state turnover,
reducing the levels of the target protein. As evident in Table 1,
the consequence of a specific inhibitor on the steady state level
(MOI = 0, i.e., in the absence of infection) is to increase stability,
increase turnover or have no effect. Notably the stability of BCL2
was unaffected by any of the inhibitors used (Table 1). Furthermore,
BAX, which was subject to the highest turnover, was stabilized
by the inhibition of all the non-proteasome mediated degradation mechanisms. The results with the BH3-only proteins BAD
and BID failed to follow an obvious pattern except in the case of
chymotrypsin-like activities (inhibited by TPCK) where decreased
inherent stability was observed (Table 1). All the other treatments
failed to significantly impact steady state levels while clearly affecting the inherent stability of BID (Table 1). The increased turnover
of BID as a result of the inhibition of the proteasome, cysteine
proteases, and chymotrypsin-like activities suggest the loss of a
stabilizing activity. In contrast, the increased steady state levels of
BID in the presence of leupeptin implicate trypsin-like activity in
the normal turnover of BID (Figure 5). The effect of the proteasome
and protease inhibitors on the infection-mediated stability of the
BCL2-family proteins further establishes the relative insensitivity of
BCL2 to infection-mediated degradation. To the contrary, a trend
indicating an infection level dependent accumulation of BCL2 in
the presence of leupeptin suggests a trypsin-like activity is specifically involved (Figure 5).
None of the inhibitors had any effect on the infection-mediated
degradation of BAX (Table 1), despite the non-proteasome inhibitors increasing the stability the protein in the absence of infection (Table 1). As a result, although the initial levels of BAX
were typically higher, their degradation was evident at the lower
multiplicities of infection (Figures 3–6). The greatest impact on
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infection-mediated stability was seen with the BH3-only proteins
BAD and BID (Table 1). Judging from the slope of the curves,
the inhibition of the proteasome effectively blocked the parasite
mediated degradation in response to infection level (Figure 3C).
This general trend is followed for leupeptin treatment (trypsin-like
activities) where for BID the apparent decreases of the mean intensity are neutralized by the significant SE (Figure 5B). This pattern
repeats for both BAD and BID following TPCK (chymotrypsin-like
activities) treatment (Figure 6B). The cysteine protease inhibitor
E64d had a minor effect in stabilizing BAD requiring a higher infection dose to observe degradation (Figure 4).
A central question and unresolved question presented by this
work is that of the source of the specific proteolytic and/or protective
activities involved. What is clear is that multiple activities broadly
focused on the class of the BCL2-family protein are involved. In
the case of the relative stability of BCL2 in response to infection the
data suggest a role for a “protective” activity that is at least partially
regulated by NFκB. This suggests an indirect mechanism where
the parasite is modulating host gene expression to sustain BCL2
levels by the combined action of increased transcription (Molestina
et al., 2003) and the potential induction of a protective activity. In
this regard the identification of an NFκB induced serpin (serine
protease inhibitor) that targets the serine protease family activities
are intriguing (Dechend et al., 1999; Mutoh et al., 2008; Jerczynska
and Pawlowska, 2009). The observation that leupeptin completely
abolishes infection-dependent BCL2 degradation at the highest
MOI is consistent with this conclusion (Figure 4).
Multiple proteolytic activities are involved in the degradation of
the pro-apoptotic BCL2-proteins. The insensitivity of BAX degradation in response to any of the inhibitors used suggests the involvement of a distinct activity. Infection could induce the activity (by
activation of a protease or elimination of an inhibitor) in the host
cell or be the consequence of a secreted parasite protease.
In the case of the BH3 only proteins BAD and BID the capacity for infection-mediated degradation is dampened or lost by the
inhibition of the proteasome (Figure 3) as well as both trypsinand chymotrypsin-like activities (Figures 5 and 6). The loss of
degradation following proteasome inhibition implicates a ubiquitin mediated turnover in the parasite induced degradation. This
would suggest a mechanism that is indirectly impacted by parasite
infection. In contrast, the effects of leupeptin and TPCK could be
explained by the activation of a host protease, or loss of an inhibitory
activity. Both trypsin and chymotrypsin are serine proteases and are
therefore potentially inhibitable by the serpin class of endogenous
serine protease inhibitors (Law et al., 2006). In addition the delivery
of a specific parasite protease into the host cytoplasm cannot be
ruled out. Such an activity has been described for the intravacuolar
bacteria of the Chlamydia species which release CPAF (Chlamydia

protease/proteasome-like activity factor) into the cytoplasm of the
host cell where they selectively target BH3 only proteins (Zhong
et al., 2001; Byrne and Ojcius, 2004; Dong et al., 2004; Fischer et al.,
2004; Ying et al., 2005). Chlamydial CPAF additionally is inhibited
by the proteasome inhibitor MG132 (Zhong et al., 2001; Byrne and
Ojcius, 2004) an inhibition profile consistent with what we observe
for T. gondii infection-mediated degradation specifically of BH3–
only proteins (Table 1). The availability of the T. gondii genome
(www.toxodb.org) allows for the identification of potential CPAFhomologs in this parasite that shares several features regarding the
establishment of its intracellular niche with Chlamydiae (Sinai and
Joiner, 1997). Of note the T. gondii genome encodes several secreted
proteases and serpins which have been shown to be secreted into the
parasitophorous vacuole but not into the host cell (Ahn et al., 2001;
Morris et al., 2002; Teo et al., 2007; Cuppari et al., 2008).
A growing body of work reveals that the efficient targeting of
cellular components by parasite effectors directly influences cellular functions (Boyle and Radke, 2009). Our work with the PVMlocalized I κB kinase activity (Molestina and Sinai, 2005a,b), the
work with the ROP-family kinases (reviewed in Peixoto et al., 2010)
and a rhoptry derived phosphatase (Gilbert et al., 2007) delivered
to the host nucleus all point to a highly refined system for host
manipulation. Notably, among the proteins found in the rhoptry
proteome are predicted proteases and peptidases (Bradley et al.,
2005) which could be delivered to the host cell like the ROP kinases.
This study presents potential targets that are directly linked into the
establishment of the replication permissive niche by enforcing the
anti-apoptotic state. Recent advances in generating targeted gene
disruptions in the parasite (Fox et al., 2009; Huynh and Carruthers,
2009) may allow the direct consequence of the elimination of
secreted proteases on the stability of the BCL-family of proteins.
In conclusion, our data support a body of evidence that the inhibition of apoptosis by T. gondii is the manifestation of a complex
reprogramming of the host cell. The systems employed to enforce
this blockade are multi-factorial and dynamic. While some parasite
effectors, directly targeting host cell proteins have been identified
the potential for novel activities including potentially proteases
reveals a new weapon in the arms race that defines the pathogen
host interaction.
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